Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Revision Skincare
Deal Size : Undisclosed
Deal Type : Partnership
Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.
Details : As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).
Product Name : Upneeq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 30, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Revision Skincare
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Athyrium Capital
Deal Size : $24.0 million
Deal Type : Private Placement
RVL Pharmaceuticals Plc Announces Insider and Athyrium-Led Financing
Details : The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.
Product Name : Upneeq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 08, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Athyrium Capital
Deal Size : $24.0 million
Deal Type : Private Placement
Lead Product(s) : Baclofen
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2022
Lead Product(s) : Baclofen
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Santen Pharmaceutical
Deal Size : $89.0 million
Deal Type : Licensing Agreement
Details : Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.
Product Name : Upneeq
Product Type : Other Small Molecule
Upfront Cash : $25.0 million
July 28, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Santen Pharmaceutical
Deal Size : $89.0 million
Deal Type : Licensing Agreement
Lead Product(s) : RVL-1201
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 21, 2018
Lead Product(s) : RVL-1201
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RVL-1201
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 25, 2018
Lead Product(s) : RVL-1201
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Osmotica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2017
Lead Product(s) : Baclofen
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Osmotica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Osmotica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2017
Lead Product(s) : Baclofen
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Osmotica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Osmotica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2016
Lead Product(s) : Baclofen
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Osmotica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RVL-1201
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 07, 2015
Lead Product(s) : RVL-1201
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable